



## US company demonstrates strong Sofra™ potential

### Highlights

- US company Tezcat Biosciences produces encouraging Sofra results
- Unique delivery system to carry Noxopharm drugs to target sites
- Collaboration progressing to next stage

**Sydney, 5 August 2025:** Clinical-stage biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce initial results from a US company testing assets from the [Sofra™](#) technology platform.

Based in New York, [Tezcat Biosciences](#) is a specialist cancer-focused company that is developing a unique delivery system that transports drugs to specific diseased cells within the body, including immune cells and cancer cells.

A strength of this delivery system is its ability to carry various drugs as payloads, and Tezcat is currently assessing how to transport novel drugs such as Noxopharm's Sofra assets. The goal is to target immune cells and explore how this approach could be used in the battle against cancer as well as chronic inflammatory diseases.

Noxopharm signed a Material Transfer Agreement with Tezcat in late 2024, and since then the American company has been evaluating the payload potential of Sofra oligonucleotides.

Tezcat conducted a series of preclinical *in vitro* studies that resulted in highly promising outcomes, principally by demonstrating that Noxopharm's oligos can be successfully attached to Tezcat's delivery system to create a novel drug candidate with strong anti-inflammatory activity.

These studies reinforce the versatility of the Sofra technology and how it can be efficiently tailored for specific use cases and administered in multiple ways, for example topically through [SOF-SKN™](#) in Noxopharm's HERACLES clinical trial, via the systemic route with [BioRay's antibody-drug conjugates](#), and now through Tezcat's innovative delivery system.

Additionally, Tezcat has [previously shown](#) that its delivery system may increase the efficacy of the drugs being delivered. This places Noxopharm in a good position to benefit from this advanced approach, greatly widens the potential therapeutic scope of Sofra oligos, and opens up promising avenues for systemic delivery in inflammatory diseases and cancer.




Figure 1 – Cells were left untreated (pink), treated with Tezcat’s delivery system (yellow), or treated with Noxopharm’s TLR7/8-inhibitory oligo tethered to Tezcat’s delivery system (blue), prior to stimulation with the TLR7 agonist resiquimod (all groups).

As predicted, the Noxopharm oligo tethered to Tezcat’s delivery system significantly dampened resiquimod-induced inflammation (blue vs pink), and there was no effect of the delivery system alone (yellow vs pink).

Mean ± S.E.M. and one-way ANOVA with uncorrected Fisher’s LSD test shown, n=3 technical replicates shown. \*\*\*p<0.001, \*\*\*\*p<0.0001, ns = not significant

Following these encouraging results, Noxopharm and Tezcat are further developing their relationship and planning additional and more complex studies in animal models. This is expected to take several months, and shareholders will be updated in due course.

Tezcat CEO Dr Craig Ramirez said: “We have been very impressed by the performance of Noxopharm’s technology in our delivery system, and the results allow us to look further into what these oligos can do in both inflammatory diseases and cancer. We are eager to progress to the next phase and will be working closely with Noxopharm to scale up our efforts.”

Noxopharm CEO Dr Gisela Mautner said: “We are very pleased to be working with Tezcat, who are operating in an area of cancer research that has significant market potential. Their targeted delivery technology represents a unique opportunity to demonstrate systemic delivery of our Sofra oligos, which could represent a valuable payload for Tezcat. This project also broadens our range of potential disease indications, including in the cancer space.

“They are committed to pushing the boundaries of innovation through developing new ideas for tackling cancer and inflammatory chronic conditions, and have conducted these studies at a rapid pace that gives us great confidence as we expand on our work together.”

**-ENDS-**

#### About the Sofra technology platform

Developed from a [breakthrough discovery](#) in the immune system, Sofra comprises a novel class of drugs targeting inflammatory and autoimmune diseases, as well as RNA therapeutics and vaccines.

For personal use only

[Sofra technology](#) has potential applications in a wide range of diseases related to the immune system such as rheumatoid arthritis, lupus and diabetes, as well as other diseases like cancer.

The global autoimmune disease therapeutics market was worth US\$163.2 billion in 2024 and is expected to reach US\$219.6 billion by 2035, while the worldwide immuno-oncology market was US\$43 billion in 2023 and is projected to hit US\$284 billion by 2033.

The proprietary platform is based on short nucleic acid sequences, the building blocks of DNA or RNA, known as oligonucleotides. These act on specific immune sensors to regulate inflammation at its source, reducing or stimulating it to control the disease.

Further information and animations: [SOF-SKN](#) / [SOF-VAC](#)

### About Noxopharm

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).

To learn more, please visit: [noxopharm.com](http://noxopharm.com)

**Investor, Corporate & Media enquiries:**

Julian Elliott

M: 0425 840 071

E: [julian.elliott@noxopharm.com](mailto:julian.elliott@noxopharm.com)

**Company Secretary:**

David Franks

T: +61 2 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

*Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.*

---

### Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.